Model systems to study the life cycle of human papillomaviruses and HPV-associated cancers

Virologica Sinica

Volumn 30, Issue 2, 2015, Pages 92-100

  Chow, Louise T ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

HPV associated cancers; human papillomaviruses (HPVs); model systems; productive program

Indexed keywords

ANIMAL CELL CULTURE; CELL IMMORTALIZATION; CERVICAL CANCER CELL LINE; EPIDERMODYSPLASIA VERRUCIFORMIS; EPITHELIUM CELL; HUMAN; HUMAN PAPILLOMA VIRUS ASSOCIATED CANCER; HUMAN PAPILLOMAVIRUS TYPE 16; KERATINOCYTE; LIFE CYCLE; MOUSE MODEL; NEOPLASM; NONHUMAN; PAPILLOMAVIRUS INFECTION; PREPUCE; PRIMARY CELL; PRIMARY HUMAN FORESKIN KERATINOCYTE; PROGENY; REVIEW; TRANSGENIC MOUSE; TROPHOBLAST; TUMOR XENOGRAFT; U2OS CELL LINE; VIRUS CARCINOGENESIS; VIRUS PARTICLE; WART VIRUS; ANIMAL; DISEASE MODEL; HOST PATHOGEN INTERACTION; ORGAN CULTURE TECHNIQUE; PAPILLOMAVIRIDAE; PHYSIOLOGY; VIROLOGY;

ANIMALIA; HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; PAPILLOMAVIRIDAE;

ANIMALS; DISEASE MODELS, ANIMAL; HOST-PATHOGEN INTERACTIONS; HUMANS; NEOPLASMS; ORGAN CULTURE TECHNIQUES; PAPILLOMAVIRIDAE;

EID: 84928668769     PISSN: 16740769     EISSN: 1995820X     Source Type: Journal    
DOI: 10.1007/s12250-015-3600-9     Document Type: Review

References (94)

1. Adams JC, Watt FM. 1989. Fibronectin inhibits the terminal differentiation of human keratinocytes. Nature, 340: 307–309.
2. Allen-Hoffmann BL, Schlosser SJ, Ivarie CA, Sattler CA, Meisner LF, O’Connor SL. 2000. Normal growth and differentiation in a spontaneously immortalized near-diploid human keratinocyte cell line, NIKS. J Invest Dermatol, 114: 444–455.
3. Asselineau D, Prunieras M. Reconstruction of “simplified’ skin: control of fabrication. 1984. Br J Dermatol, 111Suppl 27: 219–222.
4. Banerjee NS, Wang HK, Broker TR, Chow LT. 2011. Human papillomavirus (HPV) E7 induces prolonged G2 following S phase reentry in differentiated human keratinocytes. J Biol Chem, 286: 15473–115482.
5. Bedell MA, Hudson JB, Golub TR, Turek ME, Hosken M, Wilbanks GD, Laimins LA. 1991. Amplification of human papillomavirus genomes in vitro is dependent on epithelial differentiation. J Virol, 65: 2254–2260.
6. Blanton RA, Perez-Reyes N, Merrick DT, McDougall JK. 1991. Epithelial cells immortalized by human papillomaviruses have premalignant characteristics in organotypic culture. Am J Pathol, 138: 673–685.
7. Bonnez W. 2005. The HPV xenograft severe combined immunodeficiency mouse model. Methods Mol Med, 119: 203–216.
8. Borgogna C, Zavattaro E, De Andrea M, Griffin HM, Dell’Oste V, Azzimonti B, Landini MM, Peh WL, Pfister H, Doorbar J, Landolfo S, Gariglio M. 2012. Characterization of beta papillomavirus E4 expression in tumours from Epidermodysplasia Verruciformis patients and in experimental models. Virology, 423: 195–204.
9. Boyce ST, Ham RG. 1983. Calcium-regulated differentiation of normal human epidermal keratinocytes in chemically defined clonal culture and serum-free serial culture. J Invest Dermatol, 81:33s–40s.
10. Bravo IG, Félez-Sánchez M. 2015. Papillomaviruses: Viral evolution, cancer and evolutionary medicine. Evol Med Public Health, 1: 32–51.
11. Bulut G, Üren A. 2015. Generation of k14-e7/Δn87βcat double transgenic mice as a model of cervical cancer. Methods Mol Biol, 1249: 393–406.
12. Buonomo T, Carraresi L, Rossini M, Martinelli R. 2011. Involvement of aryl hydrocarbon receptor signaling in the development of small cell lung cancer induced by HPV E6/E7 oncoproteins. J Transl Med, 2011 9: 2.
13. Bzhalava D, Eklund C, Dillner J. 2015. International standardization and classification of human papillomavirus types. Virology, 476: 341–344.
14. Cancer Genome Atlas Network. 2015. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature, 517: 576–582.
15. Chen Y, Pirisi L, Creek KE. 2013. Ski protein levels increase during in vitro progression of HPV16-immortalized human keratinocytes and in cervical cancer. Virology, 444: 100–108.
16. Cheng S, Schmidt-Grimminger DC, Murant T, Broker TR, Chow LT. 1995. Differentiation-dependent up-regulation of the human papillomavirus E7 gene reactivates cellular DNA replication in suprabasal differentiated keratinocytes. Genes Dev, 9: 2335–2349.
17. Chow LT, Broker TR. 2013. Human papillomavirus infections: warts or cancer? Cold Spring Harb Perspect Biol, 5: a012997.
18. Chung SH, Lambert PF. 2009. Prevention and treatment of cervical cancer in mice using estrogen receptor antagonists. Proc Natl Acad Sci U S A, 106: 19467–19472.
19. Chung TK, Van Hummelen P, Chan PK, Cheung TH, Yim SF, Yu MY et al. 2015. Genomic aberrations in cervical adenocarcinomas in Hong Kong Chinese women. Int J Cancer, Jan 27. doi: 10.1002/ijc.29456.
20. Creek KE, Geslani G, Batova A, Pirisi L. 1995. Progressive loss of sensitivity to growth control by retinoic acid and transforming growth factor-beta at late stages of human papillomavirus type 16-initiated transformation of human keratinocytes. Adv Exp Med Biol, 375: 117–135.
21. Dollard SC, Wilson JL, Demeter LM, Bonnez W, Reichman RC, Broker TR, Chow LT. 1992. Production of human papillomavirus and modulation of the infectious program in epithelial raft cultures. Genes Dev, 6: 1131–1142.
22. Donaldson MM, Mackintosh LJ, Bodily JM, Dornan ES, Laimins LA, Morgan IM. 2013. An interaction between human papillomavirus 16 E2 and TopBP1 is required for optimum viral DNA replication and episomal genome establishment. J Virol, 86: 12806–12815.
23. Gosmann C, Frazer IH, Mattarollo SR, Blumenthal A. 2014a. IL-18, but not IL-12, induces production of IFN-γ in the immune-suppressive environment of HPV16 E7 transgenic hyperplastic skin. J Invest Dermatol, 134: 2562–2569.
24. Gosmann C, Mattarollo SR, Bridge JA, Frazer IH, Blumenthal A. 2014b. IL-17 suppresses immune effector functions in human papillomavirus-associated epithelial hyperplasia. J Immunol, 193: 2248–2257.
25. Geimanen J, Isok-Paas H, Pipitch R, Salk K, Laos T, Orav M, Reinson T, Ustav M Jr, Ustav M, Ustav E. 2011. Development of a cellular assay system to study the genome replication of highand low-risk mucosal and cutaneous human papillomaviruses. J Virol, 85: 3315–3329.
26. Genovese NJ, Banerjee NS, Broker TR, Chow LT. 2008. Casein kinase II motif-dependent phosphorylation of HPV E7 protein promotes p130 degradation and S-phase induction in differentiated human keratinocytes. J Virol, 82: 4862–4873.
27. Genovese NJ, Broker TR, Chow LT. 2011. Nonconserved lysine residues attenuate the biological function of the low-risk human papillomavirus E7 protein. J Virol, 85: 5546–5554.
28. Gomez LM, Ma Y, Ho C, McGrath CM, Nelson DB, Parry S. 2008. Placental infection with human papillomavirus is associated with spontaneous preterm delivery. Hum Reprod, 23: 709–715.
29. Gunasekharan V, Laimins LA. 2013. Human papillomaviruses modulate microRNA 145 expression to directly control genome amplification. J Virol, 87: 6037–6043.
30. Halbert CL, Demers GW, Galloway DA. 1992. The E6 and E7 genes of human papillomavirus type 6 have weak immortalizing activity in human epithelial cells. J Virol, 66: 2125–2134.
31. Henken FE, Banerjee NS, Snijders PJ, Meijer CJ, De-Castro Arce J, Rösl F, Broker TR, Chow LT, Steenbergen RD. 2011. PIK3CA-mediated PI3-kinase signaling is essential for HPV-induced transformation in vitro. Mol Cancer, 10: 71.
32. Hiroshima Y, Zhang Y, Zhang N, Maawy A, Mii S, Yamamoto M, Uehara F, Miwa S, Yano S, Murakami T, Momiyama M, Chishima T, Tanaka K, Ichikawa Y, Bouvet M, Murata T, Endo I, Hoffman RM. 2015. Establishment of a patient-derived orthotopic Xenograft (PDOX) model of HER-2-positive cervical cancer expressing the clinical metastatic pattern. PLoS One, 10: e0117417.
33. Honegger A, Schilling D, Bastian S, Sponagel J, Kuryshev V, Sültmann H, Scheffner M, Hoppe-Seyler K, Hoppe-Seyler F. 2015. Dependence of Intracellular and Exosomal microRNAs on Viral E6/E7 Oncogene Expression in HPV-positive Tumor Cells. PLoS Pathog, 11: e1004712.
34. Hong S, Dutta A, Laimins LA. 2015. The acetyltransferase tip60 is a critical regulator of the differentiation-dependent amplification of human papillomaviruses. J Virol, 89: 4668–4675.
35. Hong S, Laimins LA. 2013. The JAK-STAT transcriptional regulator, STAT-5, activates the ATM DNA damage pathway to induce HPV 31 genome amplification upon epithelial differentiation. PLoS Pathog, 9: e1003295.
36. Hong S, Mehta KP, Laimins LA. 2011. Suppression of STAT-1 expression by human papillomaviruses is necessary for differentiation-dependent genome amplification and plasmid maintenance. J Virol, 85: 9486–9494.
37. Hoskins EE, Morreale RJ, Werner SP, Higginbotham JM, Laimins LA, Lambert PF, Brown DR, Gillison ML, Nuovo GJ, Witte DP, Kim MO, Davies SM, Mehta PA, Butsch Kovacic M, Wikenheiser-Brokamp KA, Wells SI. 2012. The fanconi anemia pathway limits human papillomavirus replication. J Virol, 86: 8131–8138.
38. Howley PM, Pfister HJ. 2015. Beta genus papillomaviruses and skin cancer. Virology, Feb 24. pii: S0042-6822(15)00047-1. doi: 10.1016/j.virol.2015.02.004.
39. Howie HL, Katzenellenbogen RA, Galloway DA. 2009. Papillomavirus E6 proteins. Virology, 384: 324–334.
40. Hufbauer M, Lazić D, Reinartz M, Akgül B, Pfister H, Weissenborn SJ. 2011. Skin tumor formation in human papillomavirus 8 transgenic mice is associated with a deregulation of oncogenic miRNAs and their tumor suppressive targets. J Dermatol Sci, 64: 7–15.
41. Hurlin PJ, Kaur P, Smith PP, Perez-Reyes N, Blanton RA, McDougall JK. 1991. Progression of human papillomavirus type 18-immortalized human keratinocytes to a malignant phenotype. Proc Natl Acad Sci U S A, 88: 570–574.
42. Jabbar S, Strati K, Shin MK, Pitot HC, Lambert PF. 2010 Human papillomavirus type 16 E6 and E7 oncoproteins act synergistically to cause head and neck cancer in mice. Virology, 407: 60–67.
43. Jagu SJ, K Kwak, Schiller JT, Lowy DR, Kleanthous H, Kalnin K, Wang HK, Chow LT, Huh WK, Jaganathan K, Chivukula S, Roden RB. 2013. Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine. J Virol, 87: 6127–6136.
44. Jian Y, Schmidt-Grimminger DC, Chien WM, Wu X, Broker TR, Chow LT. 1988. Post-transcriptional induction of p21cip1 protein by human papillomavirus E7 inhibits unscheduled DNA synthesis reactivated in differentiated keratinocytes. Oncogene, 17: 2027–2038.
45. Jung ID, Shin SJ, Lee MG, Kang TH, Han HD, Lee SJ, Kim WS, Kim HM, Park WS, Kim HW, Yun CH, Lee EK, Wu TC, Park YM. 2014. Enhancement of tumor-specific T cell-mediated immunity in dendritic cell-based vaccines by mycobacterium tuberculosis heat shock protein X. J Immunol, 193: 1233–1245.
46. Kho EY, Wang HK, Banerjee NS, Broker TR, Chow LT. 2013. HPV-18 E6 mutants reveal p53 modulation of viral DNA amplification in organotypic cultures. Proc Natl Acad Sci USA, 110: 7542–7549.
47. Lambert PF, Ozbun MA, Collins A, Holmgren S, Lee D, Nakahara T. 2005. Using an immortalized cell line to study the HPV life cycle in organotypic “raft” cultures. Methods Mol Med, 119: 141–155.
48. Lazarczyk M, Cassonnet P, Pons C, Jacob Y, Favre M. 2009. The EVER proteins as a natural barrier against papillomaviruses: a new insight into the pathogenesis of human papillomavirus infections. Microbiol Mol Biol Rev, 73: 348–370.
49. Lee SA, Belyaeva OV, Wu L, Kedishvili NY. 2011. Retinol dehydrogenase 10 but not retinol/sterol dehydrogenase(s) regulates the expression of retinoic acid-responsive genes in human transgenic skin raft culture. J Biol Chem, 286: 13550–13560.
50. Lin KY, Guarnieri FG, Staveley-O’Carroll KF, Levitsky HI, August JT, Pardoll DM, Wu TC. 1996. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res, 56: 21–26.
51. Liu Y, You H, Hermonat PL. 2005. Studying the HPV life cycle in 3A trophoblasts and resulting pathophysiology. Methods Mol Med, 119: 237–245
52. Martinez I, Gardiner AS, Board KF, Monzon FA, Edwards RP, Khan SA. 2008. Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cells. Oncogene, 27: 2575–2582.
53. Maufort JP, Shai A, Pitot HC, Lambert PF. 2010. A role for HPV16 E5 in cervical carcinogenesis. Cancer Res, 70: 2924–2931.
54. McKenna DJ, Patel D, McCance DJ. 2014. miR-24 and miR-205 expression is dependent on HPV onco-protein expression in keratinocytes. Virology, 448: 210–216.
55. McLaughlin-Drubin ME, Meyers C. Propagation of infectious, high-risk HPV in organotypic “raft” culture. 2005. Methods Mol Med, 119: 171–186.
56. McLaughlin-Drubin ME, Münger K. 2009. Oncogenic activities of human papillomaviruses. Virus Res, 143: 195–208.
57. Melar-New M, Laimins LA. 2010. Human papillomaviruses modulate expression of microRNA 203 upon epithelial differentiation to control levels of p63 proteins. J Virol, 84: 5212–5221.
58. Meyers C, Frattini MG, Hudson JB, Laimins LA. 2002. Biosynthesis of human papillomavirus from a continuous cell line upon epithelial differentiation. Science, 257: 971–973.
59. Moody CA, Laimins LA. 2009. Human papillomaviruses activate the ATM DNA damage pathway for viral genome amplification upon differentiation. PLoS Pathog, 5: e1000605.
60. Moody CA, Laimins LA. 2010. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer, 10: 550–560.
61. Ocadiz-Delgado R, Marroquin-Chavira A, Hernandez-Mote R, Valencia C, Manjarrez-Zavala ME, Covarrubias L, Gariglio P. 2009. Induction of focal epithelial hyperplasia in tongue of young BK6-E6/E7 HPV16 transgenic mice. Transgenic Res, 18: 513–527.
62. Ojesina AI, Lichtenstein L, Freeman SS, Pedamallu CS, Imaz-Rosshandler I, Pugh TJ et al. 2014. Landscape of genomic alterations in cervical carcinomas. 2014. Nature, 506: 371–375.
63. Park JW, Shin MK, Lambert PF. 2014. High incidence of female reproductive tract cancers in FA-deficient HPV16-transgenic mice correlates with E7’s induction of DNA damage response, an activity mediated by E7’s inactivation of pocket proteins. Oncogene, 33: 3383–3391.
64. Park JW, Shin MK, Pitot HC, Lambert PF. 2013. High incidence of HPV-associated head and neck cancers in FA deficient mice is associated with E7’s induction of DNA damage through its inactivation of pocket proteins. PLoS One, 8: e75056.
65. Peng S, Wang JW, Karanam B, Wang C, Huh WK, Alvarez RD, Pai SI, Hung CF, Wu TC, Roden RB. 2015. Sequential cisplatin therapy and vaccination with HPV16 E6E7L2 fusion protein in saponin adjuvant GPI-0100 for the treatment of a model HPV16+ cancer. PLoS One, 10: e116389.
66. Regan JA, Laimins LA. 2013. Viral transformation of epithelial cells. Methods Mol Biol, 945: 449–465
67. Sankovski E, Männik A, Geimanen J, Ustav E, Ustav M. 2014. Mapping of beta papillomavirus human papillomavirus 5 transcription and characterization of viral-genome replication function. J Virol, 88: 961–973.
68. Sarkola ME, Grénman SE, Rintala MA, Syrjänen KJ, Syrjänen SM. 2008. Human papillomavirus in the placenta and umbilical cord blood. Acta Obstet Gynecol Scand, 87: 1181–1188.
69. Schütze DM, Kooter JM, Wilting SM, Meijer CJ, Quint W, Snijders PJ, Steenbergen RD. 2015. Longitudinal assessment of DNA methylation changes during HPVE6E7-induced immortalization of primary keratinocytes. Epigenetics, 10: 73–81.
70. Shishodia G, Verma G, Srivastava Y, Mehrotra R, Das BC, Bharti AC. 2014. Deregulation of microRNAs Let-7a and miR-21 mediate aberrant STAT3 signaling during human papillomavirus-induced cervical carcinogenesis: role of E6 oncoprotein. BMC Cancer, 14: 996.
71. Siolas D, Hannon GJ. 2013. Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer Res, 73: 5315–5319.
72. Son J, Park JW, Lambert PF, Chung SH. 2014. Requirement of estrogen receptor alpha DNA-binding domain for HPV oncogene-induced cervical carcinogenesis in mice. Carcinogenesis, 35: 489–496.
73. Stanley MA, Browne HM, Appleby M, Minson AC. 1989. Properties of a non-tumorigenic human cervical keratinocyte cell line. Int J Cancer, 43: 672–676.
74. Stanley JR, Yuspa SH. 1983. Specific epidermal protein markers are modulated during calcium-induced terminal differentiation. J Cell Biol, 96: 1809–1814.
75. Steenbergen RD, Parker JN, Isern S, Snijders PJ, Walboomers JM, Meijer CJ, Broker TR, Chow LT. 1998. Viral E6-E7 transcription in the basal layer of organotypic cultures without apparent p21cip1 protein precedes immortalization of human papillomavirus type 16- and 18-transfected human keratinocytes. J Virol, 72: 749–757.
76. Stelzer MK, Pitot HC, Liem A, Schweizer J, Mahoney C, Lambert PF. 2010. A mouse model for human anal cancer. Cancer Prev Res (Phila), 3: 1534–1541.
77. Thomas MK, Pitot HC, Liem A, Lambert PF. 2011. Dominant role of HPV16 E7 in anal carcinogenesis. Virology, 421: 114–118.
78. Tran le S, Bergot AS, Mattarollo SR, Mittal D, Frazer IH. 2014. Human papillomavirus E7 oncoprotein transgenic skin develops an enhanced inflammatory response to 2,4-dinitrochlorobenzene by an arginase-1-dependent mechanism. J Invest Dermatol, 134:2438–2446.
79. Viarisio D, Decker KM, Aengeneyndt B, Flechtenmacher C, Gissmann L, Tommasino M. 2013. Human papillomavirus type 38 E6 and E7 act as tumor promoters during chemically induced skin carcinogenesis. J Gen Virol, 94: 749–752.
80. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV et al. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 189: 12–19.
81. Wald AI, Hoskins EE, Wells SI, Ferris RL, Khan SA. 2011. Alteration of microRNA profiles in squamous cell carcinoma of the head and neck cell lines by human papillomavirus. Head Neck, 33: 504–512.
82. Wang HK, Duffy AA, Broker TR, Chow LT. 2009. Robust production and passaging of infectious HPV in squamous epithelium of primary human keratinocytes. Genes Dev, 23: 181–194.
83. Wang X, Meyers C, Wang HK, Chow LT, Zheng ZM. 2011. Construction of a full transcription map of human papillomavirus type 18 during productive viral infection. J Virol. 85: 8080–8092.
84. Wang X, Tang S, Le SY, Lu R, Rader JS, Meyers C, Zheng ZM. 2008. Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One, 3: e2557.
85. Wang X, Wang HK, Li Y, Hafner M, Banerjee NS, Tang S, Briskin D, Meyers C, Chow LT, Xie X, Tuschl T, and Zheng ZM. 2014. miRNAs are biomarkers of oncogenic HPV infections, Proc Natl Acad Sci U S A, 111: 4362–4267.
86. Wang X, Wang HK, McCoy JP, Banerjee NS, Rader JS, Broker TR, Meyers C, Chow LT, Zheng ZM. 2009. Oncogenic HPV infection interrupts the expression of tumor-suppressive miR-34a through viral oncoprotein E6. RNA, 15: 637–647.
87. Wilson JL, Dollard SC, Chow LT, Broker TR. 1992. Epithelial-specific gene expression during differentiation of stratified primary human keratinocyte cultures. Cell Growth Diff, 3: 471–483.
88. Wilson R, Laimins LA. 2005. Differentiation of HPV-containing cells using organotypic “raft” culture or methylcellulose. Methods Mol Med, 119:157–69.
89. Xu H, Pirisi L, Creek KE. 2015. Six1 overexpression at early stages of HPV16-mediated transformation of human keratinocytes promotes differentiation resistance and EMT. Virology, 474: 144–153.
90. Yablonska S, Hoskins EE, Wells SI, Khan SA. 2013. Identification of miRNAs dysregulated in human foreskin keratinocytes (HFKs) expressing the human papillomavirus (HPV) Type 16 E6 and E7 oncoproteins. Microrna, 2: 2–13.
91. You H, Liu Y, Agrawal N, Prasad CK, Edwards JL, Osborne AF, Korourian S, Lowery CL, Hermonat PL. 2008. Multiple human papillomavirus types replicate in 3A trophoblasts. Placenta, 29: 30–38.
92. Zhang J, Li S, Yan Q, Chen X, Yang Y, Liu X, Wan X. 2013. Interferon-β induced microRNA-129-5p down-regulates HPV-18 E6 and E7 viral gene expression by targeting SP1 in cervical cancer cells. PLoS One, 8: e81366.
93. Zheng ZM, Wang X. 2011. Regulation of cellular miRNA expression by human papillomaviruses. Biochim Biophys Acta, 1809: 668–677.
94. zur Hausen H. 2009. Papillomaviruses in the causation of human cancers — a brief historical account. Virology, 384:260–265.